FDA Hepatitis Update - FDA Antiviral Advisory Committee April 28, 2011 meeting background materials available: telaprevir for Hepatitis C

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: FDA Hepatitis Update - FDA Antiviral Advisory Committee April 28, 2011 meeting background materials available: telaprevir for Hepatitis C

	 You are receiving this message as a subscriber to the FDA hepatitis electronic list serve. The purpose of the list serve is to relay important information about viral hepatitis-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

Background materials for the April 28 FDA Antiviral Advisory Committee meeting to discuss telaprevir, a direct acting antiviral (DAA) intended for the treatment of hepatitis C are available on the FDA web site through the following links... 

• April 28, 2011: Antiviral Drugs Advisory Committee Meeting Announcement
• Draft Agenda for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 85KB)
• Draft Questions for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 21KB)
• Draft Meeting Roster for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 102KB)
• Committee Roster for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 25KB)
• Webcast Information for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee (PDF - 16KB)
• Briefing Information for the April 28, 2011 Meeting of the Antiviral Drugs Advisory Committee

Richard Klein
Office of Special Health Issues
Food and Drug Administration

Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@xxxxxxxxxxxxxxx
• Other inquiries? webmail@xxxxxxxxxx

U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420